ReviewCancer management and research2020
The Diagnosis, Treatment, Prognosis and Molecular Pathology of Borderline Ovarian Tumors: Current Status and Perspectives.
Review in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Ovulation induction drug and ovarian cancer: an updated systematic review and meta-analysis.Journal of ovarian research · 2023Pooled it
- Review
- Ovarian borderline mucinous tumor with carcinosarcomatous mural nodule: a case report of a rare entity and review of the literature.Frontiers in medicine · 2026Article
- Survival analysis of borderline ovarian tumors: a 23-year retrospective study in a Middle Eastern cohort.BMC women's health · 2025Article
- Article
- Development and Validation of Differential Diagnosis Models and Nomograms Based on Serum D-Dimer and Other Multimodal Information for Borderline and Benign Epithelial Ovarian Tumors: A Multicenter Study.Diagnostics (Basel, Switzerland) · 2025Article
- A new risk algorithm combining D-dimer and HE4 differentiates borderline tumor from patients with ovarian tumor.Translational cancer research · 2025Article
- Giant borderline ovarian tumours - review of the literature.Open medicine (Warsaw, Poland) · 2025Review
- Case Report: Serous borderline ovarian tumor and extensive abdominopelvic endometriosis mimicking advanced epithelial ovarian cancer in a postmenopausal patient.Frontiers in medicine · 2025Article
- Transcriptome Concordance Between Borderline Tumors and Endometrioid Carcinoma: An Integrative Genomic Analysis.Cancer medicine · 2025Article
- Liquid biopsy in ovarian cancer: advantages and limitations for prognosis and diagnosis.Medical oncology (Northwood, London, England) · 2023Review
- Alcohol intake and the risk of epithelial ovarian cancer.Cancer causes & control : CCC · 2023Article
- Borderline ovarian tumor and MRI evaluation of a case report.Radiology case reports · 2022Article
- Novel Optical Biosensor Based on a Nano-Gold Coated by Schiff Base Doped in Sol/Gel Matrix for Sensitive Screening of Oncomarker CA-125.ACS omega · 2021Article
- Synergistic AHR Binding Pathway with EMT Effects on Serous Ovarian Tumors Recognized by Multidisciplinary Integrated Analysis.Biomedicines · 2021Article
- Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer.BMC cancer · 2021Article
- Nationwide population-based study of prevalence and trend of borderline ovarian tumors in the Republic of Korea.Scientific reports · 2021Article
- Dysregulated Immunological Functionome and Dysfunctional Metabolic Pathway Recognized for the Pathogenesis of Borderline Ovarian Tumors by Integrative Polygenic Analytics.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Borderline ovarian tumors (BOTs) are a type of low malignant potential tumor that is typically associated with better outcomes than ovarian cancer. Indeed, its 10-year survival rate is as high as 95%. However, there is a small subset of patients who experience relapse and eventually die. It has been shown that the prognosis of BOTs was based on pathological diagnosis, the age at diagnosis, pre-operative carbohydrate antigen 125 level, invasive implants, and micropapillary patterns. Now the molecular-targeted therapy and molecular-genetic diagnosis have developed into a form of precision medicine. Recent studies on extensive molecular characterizations and molecular pathological mechanisms of BOTs have helped us understand the genomic landscapes of BOTs, and therefore BOTs could be reclassified into biologically and clinically more accurate and effective subtypes. The purpose of this review is to summarize current status for the diagnosis and treatment of BOTs and to describe the research progress on molecular pathologies, with a goal of providing a theoretical perspective for the diagnosis and treatment of BOTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.